A Comparison of Glycemic Parameters and Their Relationship with C-Peptide and Proinsulin Levels During the Honeymoon and Non-honeymoon Periods in Children with Type 1 Diabetes Mellitus - a Cross-Sectional Study

Gül Yesiltepe-Mutlu (gulyesiltepe@gmail.com)  
Koc Universitesi Tip Fakultesi  https://orcid.org/0000-0003-3919-7763

Merve Çapacı  
Koc Universitesi Tip Fakultesi

Ecem Can  
Koç University Hospital, Division of Pediatric Endocrinology and Diabetes

Tuğba Gökçe  
Koç University Hospital, Division of Pediatric Endocrinology and Diabetes

Gizem Bayrakçı  
Koç University Hospital, Division of Pediatric Endocrinology and Diabetes

Serra Muradoğlu  
Koç University Hospital, Division of Pediatric Endocrinology and Diabetes

Said İncir  
Koç University Hospital, Department of Biochemistry

Esra Papatya Çakır  
Bakirkoy Dr Sadi Konuk Eğitim ve Arastirma Hastanesi

Şükrü Hatun  
Koç University School of Medicine, Division of Pediatric Endocrinology and Diabetes

Research article

Keywords: Type 1 diabetes, honeymoon, C-peptide, Proinsulin

DOI: https://doi.org/10.21203/rs.3.rs-74900/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Background**: Currently, there is a lack of data relating to glycemic parameters and their relationship with C-peptide (CP) and proinsulin (PI) during the honeymoon period in type 1 diabetes mellitus (T1D). The aim of this study was to evaluate glycemic parameters in children with T1D who are in the honeymoon period using intermittently scanned continuous glucose monitoring systems (isCGMS) and to investigate any relationships between CP and PI levels.

**Methods**: The study included 21 children who were in the honeymoon period and 31 children who were not. A cross-sectional, non-randomized study was performed. Demographic, clinical data were collected and 2 week- isCGMS data were retrieved.

**Results**: The Serum CP showed a positive correlation with time-in-range in the honeymoon period (p:0.03), however PI showed no correlations with glycemic parameters in both periods. The Serum CP and PI levels and the PI:CP ratio were significantly higher in the honeymoon group than in the non-honeymoon group. In the non-honeymoon group, the PI level was below 0.1 pmol/L (which is the detectable limit) in only 2 of the 17 cases as compared with none in the honeymoon group. Similarly, only 2 of the 17 children in the non-honeymoon group had CP levels of less than 0.2 nmol/L, although both had detectable PI levels. Overall time-in-range (3.9-10 mmol/L) was significantly high in the honeymoon group. In contrast, the mean sensor glucose levels, time spent in hyperglycemia, and coefficient of variation levels (32.2 vs 40.5%) were significantly low in the honeymoon group.

**Conclusions**: While the CP levels did have an effect on glycemic parameters during the honeymoon period, there was no correlation between PI levels and glycemic parameters. In terms of glycemic parameters during the honeymoon period, the CP level had a significant correlation with the TIR value. CP seems to be a useful biochemical tool, while PI was not a sensitive biochemical parameter. Further studies are needed to determine if PI might prove to be a useful parameter in clinical follow-up.

Background

The transient recovery period of beta-cell function, after initiation of insulin therapy in patients with newly diagnosed type 1 diabetes mellitus, is referred to as the 'honeymoon' or remission phase (RP). The clinical significance of this period lies in the maintenance of glycemic control characterized by a reduction in insulin requirements. Previous controlled trials on the natural course of beta cell function recovery reported the prevalence of remission as 60%, (1) with a duration ranging from 1 month to as long as 13 years (2). To achieve better glycemic control throughout the remission phase, several studies focused on the factors influencing the natural course of remission, such as severity of presentation, age at diagnosis, gender, and effects of autoantibodies. Nevertheless, the glycemic parameters and variability in these parameters during the remission period remain unknown.

RP is defined as an insulin dose-adjusted hemoglobin A1c (HbA1c) (IDAA1c) of equal to or less than 9, where IDAA1c is equal to the sum of HbA1c (%) and mmol/mol and 4 times the insulin dose (units/kg/day) (1). However, this definition based on insulin doses and HbA1c is not sufficient in terms of glycemic variability, insulin sensitivity, and episodes of hypoglycemia and hyperglycemia. Furthermore, there are no definite cut-off values for C-peptide (CP) and proinsulin (PI) levels for the definition of the honeymoon period in type 1 diabetes (T1D). However, the measurement of the CP levels for the definition of the remission period has been established and is a laborious and expensive process. Additionally, an IDAA1C level of 9 has been shown to correspond to a substantially increased predicted stimulated C-peptide (CP) level of 300 pmol / l (3).

Normal insulin biosynthesis is a multi-step process, beginning with a pre-prohormone, pre-pro-insulin, which is then converted to proinsulin (PI). PI becomes incorporated into a new “immature” beta-granule, where it is subsequently cleaved into insulin and CP via prohormone convertases (PCSK1, PCSK2, and carboxypeptidase E) (4). It has been shown that the PI to CP ratio (PI:CP) increases in individuals at risk of diabetes and at the time of diagnosis of diabetes. On the other hand, Watkins et al. examined PI levels at the time of T1D diagnosis, shortly after diagnosis, and during the honeymoon period and found that the
PI level was higher during the honeymoon period than that at the time of diagnosis (5). However, the importance of neither CP nor PI levels in clinical practice and their effects on glycemic parameters have been investigated in detail.

In the past, only the HbA1C level was taken into account for defining glycemic control in diabetes. However, new glycemic parameters have emerged in the light of recent advances in diabetes technology. Currently, the definition of *honeymoon period* or RP is still based only on HbA1C levels and insulin doses and there are few studies evaluating other glycemic parameters in this period. In the light of recent technological developments, this study aimed to evaluate the glycemic parameters in children with T1D who are in RP (honeymoon period) and compare them with those who are not in this phase using intermittently scanned continuous glucose monitoring systems (isCGMS). The study also aimed to investigate the relationships between PI and CI levels and glycemic parameters in order to draw comparisons between the honeymoon and non-honeymoon periods.

**Methods**

**Subjects**

The study was conducted between March 2018 and 2019 and included 21 children with T1D who were in RP (the honeymoon group) and 31 children with T1D who had been diagnosed at least 2 years before the enrollment and who were not in RP (the non-honeymoon group). The inclusion criteria required an age of 5 to 18 years and being under multiple-dose insulin injection therapy and isCGMS. The exclusion criteria were the presence of concomitant diseases that could influence metabolic control, the use of an insulin infusion pump and having HbA1C level above 9% (75 mmol/mol) (A consort flow diagram is showed in figure 1).

**Study design**

A cross-sectional, non-randomized study was performed. The study protocol was approved by the Koç University Committee on Human Research (reference number:2018.022.IRB1.004). Written consent was obtained from the parents along with assent from the adolescents as required by the local institutional review board regulations.

A partial remission phase was defined as an insulin dose adjusted HbA1c (IDAA1c) of equal to or less than 9 (1). Demographic, socioeconomic, and clinical data were collected from medical records and from interviews with the participants and parents. Also, 2 weeks’ isCGMS data were retrieved using the Free-Style Libre software in the outpatient pediatric endocrinology clinic. In addition to the software report, the raw data were used for statistical analysis and assessed according to continuous glucose monitoring systems (CGMS) consensus report (6). Random (mostly non-fasting) serum samples were collected for measurement of CP and PI during the routine follow-up visits.

**Laboratory analyses**

For the measurement of CP and PI, samples were collected into dry tubes and centrifuged promptly (3500 g) for 10 minutes at +4 °C. The sera were separated in aliquots and frozen immediately at −80 °C. Serum CP and PI levels were determined by competitive ELISA using commercial kits (DRG Instruments GmbH, Germany). Intra- and inter-CVs were 6.54% and 9.33% for CP, and 4.3% and 6.8% for PI, respectively. The detection limit was 0.1 pmol/L for PI (7). HbA1c levels were analyzed immediately after collecting blood samples into K$_2$-EDTA-added tubes on an ADAMS A1c Lite HA-8380V analyzer (Arkay) using the HPLC (Reversed-phase cation-exchange liquid chromatography) method. Sustained levels of CP were considered to be consistent readings greater than 0.2 nmol/l (8).

**Statistical Analyses**

The sample size calculation was made using OpenEpi Statistical Software version 3.01 (9). Type 1 error of the study is $\alpha = 0.05$, the power of the study is $1-\beta = 0.80$, and the number of samples was calculated as 18 per group. A total of at least 40 people had to be included in the study, 20 per group, with an appendix of approximately ten percent loss. The other statistical
analyses were conducted using SPSS statistical software version 22 (USA). Descriptive statistics included means, standard deviation (SD), median, interquartile range, and proportions when appropriate. Correlations between CP, PI and glycemic parameters were computed using Spearman's correlation coefficient. For continuous variables, mean ± standard deviation and median values were used for variables with and without normal distribution, respectively. For continuous variables, the Student's t-test was used for normally distributed data and the Mann-Whitney U-test was used for data without normal distribution.

**Results**

The two groups were similar in terms of age and gender. As expected, the mean diabetes duration, daily insulin dose, HbA1c, IDDA1c, estimated HbA1c levels were significantly lower in the honeymoon group compared with the non-honeymoon group. However, the Serum CP and PI levels and the PI:CP ratio were significantly higher in the honeymoon group than those in the non-honeymoon group. The demographic characteristics and laboratory findings of the two groups are given in Table 1. A total of 17 children in each group agreed to give serum samples for the measurement of PI and CP. In the non-honeymoon group, PI level was below 0.1 pmol/L (which is the detectable limit) in only 2 of the 17 cases as compared with none in the honeymoon group. Similarly, only 2 of the 17 children in the non-honeymoon group had CP levels of less than 0.2 nmol / L, although both had detectable PI levels.

When the glycemic parameters were compared in the two groups (Table 2), overall time-in-range, day-time and night-time levels were significantly higher in the honeymoon group. In contrast, the mean sensor glucose levels (overall, day-time and night-time), the mean time spent in level 1 and level 2 hyperglycemia overall, day-time and night-time, the median time spent in level 1 hypoglycemia (<3.9 mmol/L) day-time, and the mean coefficient of variation (CV) and SD levels were all significantly lower in the honeymoon group.

However, the median time spent in level 1 hypoglycemia (<3.9 mmol/L) overall and night-time were similar in the two groups.

In correlation analyses (Table 3), the serum CP showed a positive correlation with time-in-range (3.9-10 mmol/L) in the honeymoon group (figure 2), along with inverse correlations with the mean sensor glucose, mean sensor glucose SD and the median time spent in level 1 hyperglycemia. In the non-honeymoon group, serum CP was positively correlated with the time spent in level 1 hypoglycemia and level 1 hyperglycemia. However, serum PI showed no correlations with glycemic parameters in both groups (figure 3).

**Discussion**

Recent developments in continuous and intermittently scanned continuous glucose monitoring systems provide not only more efficient regulation of type 1 diabetes treatment, but also new information on glycemic parameters from the time of diagnosis. In this study, by using intermittently scanned glucose monitoring systems, the glycemic parameters of children with type 1 diabetes who are in RP and those who are not in RP were compared. As expected, the glycemic parameters in the RP were found to be closer to the target levels but were far from those of non-diabetic subjects (10). It was found that while CP levels did have an effect on glycemic parameters during the honeymoon period, there was no correlation between PI levels and glycemic parameters. In terms of glycemic parameters during the honeymoon period, the CP level had a significant correlation with the TIR value. CP seems to be a useful biochemical tool, while PI was not a sensitive biochemical parameter.

New parameters are needed to define the honeymoon or preserved beta-cell reserve period. Although several studies (11-13) focused on the honeymoon period and investigated honeymoon-related factors, data related to the glycemic parameters during the honeymoon period are limited. Meng et al. examined the relationship between blood glucose fluctuations during various phases of diabetes and oxidative stress and showed that the mean glucose, glucose SD, the mean amplitude of glycemic excursions (MAGE) and incremental area under the blood glucose curve (IAUC) levels during the honeymoon period were lower than those during the acute metabolic disturbance and long-standing phases (14). Similarly, in our study, the
mean sensor glucose level, SD value, CV value, time-in-range, time in hyperglycemia were found to be lower in the honeymoon group, suggesting a better metabolic control (Table 2). While the mean CV of 32.3% was lower than the target value of 36% in the CGMS consensus, (6) the mean SD value was higher than that found in a recent study analyzing the CGMS data of healthy children (9). In addition, time spent in level 1 hypoglycemia was found to be similar in the honeymoon vs. non-honeymoon groups, indicating that glycemic control in RP is restricted.

CP is a useful and widely used method of assessing pancreatic beta-cell function. The formula for IDAA1c was derived using a higher CP cut-off value of 300 pmol/L. Therefore, although it previously played a role in defining the honeymoon phase, (3), it is no longer used to define the honeymoon phase. Venous blood CP levels can be measured in the random, fasting, or stimulated state. Random samples are taken at any time during the day without consideration of recent food intake, whereas fasting samples are taken after an 8 to 10 hours fast (8). In the present study, serum CP levels were measured in the random state, and as expected the mean CP level was significantly higher in the honeymoon group than in the non-honeymoon group. Although CP is a widely accepted biochemical parameter for pancreatic beta-cell reserve, data on the association between CP levels and glycemic parameters are very limited. In the present study, the presence of a correlation between CP levels and glycemic parameters was evaluated. In the honeymoon group, the mean CP level was inversely correlated with the mean sensor glucose and SD glucose whereas it positively correlated with TIR. These findings support that CP might be a relevant biochemical parameter in the honeymoon phase. However, the presence of a positive correlation between CP and time in both level 1 hypoglycemia and level 1 hyperglycemia in the non-honeymoon group suggests that CP is not a reliable parameter when it is low.

Recent studies reported an increased risk of developing 5-year T1D in antibody-positive first-degree relatives having an increased PI / CP ratio (15). Similarly, the PI/CP ratio was found to be higher at the time of diagnosis of diabetes compared with the control group (16). Although PI is used as a beta-cell stress marker, two recent studies showed that PI secretion was maintained for a long time and that the level of CP was still detectable in individuals with T1D (17,18). In our study, both the PI level and PI / CP ratio were significantly higher in the honeymoon group. In the non-honeymoon group, however, two children had CP levels below the measurable limit despite detectable PI levels and two children had PI levels below the measurable limit despite measurable CP levels. Due to the small size of the patient groups, it is difficult to comment on the differences in the maintenance of CP and PI secretions. In this study, no significant correlation was detected between proinsulin levels and glycemic parameters in any group, suggesting that proinsulin is not as clinically reliable as CP in the management of diabetes.

One of the main limitations of our study was the random measurement of CP and PI levels. These measures may have been affected by the degree of fasting, which was not taken into account because we recruited patients during scheduled outpatient follow-up visits. Measurements of stimulated CP and PI secretions using tests such as a mixed-meal tolerance test may be beneficial, as well. However, this study design would require more inconvenience to the participants and their families. Moreover, Watkins et al conducted a research by random sampling for the CP and PI measurement in order to evaluate the β-cell function in persons with T1D (5) and Leighton et al in their review article had stated that venous blood CP levels can be measured in the random, fasting, or stimulated state (8). Another limitation was the lack of simultaneous blood glucose measurements with the use of isCGMS which does not require calibration. The accuracy of isCGMS was reported to be lower during hypoglycemia than during euglycemia and hyperglycemia (19). However, time spent in level 1 hypoglycemia was not high and similar in both groups. Despite these limitations, we feel that this pilot study is important as it is the first study to evaluate glycemic parameters in the honeymoon period with the use of isCGMS data and to examine the relationship between these parameters and Beta-cell reserve markers CP and PI. There is no doubt that a future study with larger patient numbers would show more generalizable results.

In conclusion, although the glycemic profile during the honeymoon period was better than that in the non-honeymoon group, the glycemic variability during this period was not as low as expected. It is also important to continue efforts to improve and maintain metabolic control during the honeymoon period. Subcutaneous insulin infusion or automated insulin delivery systems may help to achieve better glycemic control in the remission phase as well. CP seems to be a useful biochemical
tool, while PI was not a sensitive biochemical parameter. Further studies are needed to determine if PI might prove to be a useful parameter in clinical follow-up.

**Abbreviations**

CP: C-peptide  
PI: Proinsulin  
T1D: Type 1 Diabetes  
isCGMS: intermittently scanned continuous glucose monitoring systems  
RP: Remission Phase  
HbA1c: Hemoglobin A1C  
IDAA1c: Insulin dose-adjusted hemoglobin A1c  
CGMS: Continuous glucose monitoring systems  
SD: Standard Deviation  
CV: Coefficient of Variation  
MAGE: the Mean amplitude of glycemic excursions  
IAUC: Incremental area under the blood glucose curve

**Declarations**

**Consent for publication:** Not applicable

**Availability of data and materials:** The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interest:** The authors declare that they have no competing interest.

**Ethics approval and consent to participate:** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study protocol was approved (approval number:2018.022.IRB1.004) by the local Institutional Review Board (IRB). Informed consent was obtained from all individual participants involved in the study. Informed consent was obtained from the parents/guardians of the minors included in this study (minors are considered anyone under the age of 16).

**Funding:** This research did not receive any specific grant.

**Author contributions:** GYM, MÇ, EC, TG, GB, SM, SI, EPÇ, ŞH contributed to the study concept and design. GYM and ŞH supervised the study. GYM, MÇ, EC and GB collected data. All authors participated in data analysis and interpretation. The manuscript was drafted by GYM and MÇ, reviewed by GYM, MÇ, EC, TG, GB, SM, SI, EPÇ, ŞH and edited by GYM and ŞH. All contributing authors approved the final version of the manuscript.

**Acknowledgement:** The authors would like to thank all the children with type 1 diabetes and their parents who participated in our study and Alan J. Newson for English language editing.
1. Chetan MR, Charlton MH, Thompson C, Dias RP, Andrews RC, Narendran P. The Type 1 diabetes 'honeymoon' period is five times longer in men who exercise: a case–control study. Diabetic Medicine. 2019 Jan;36(1):127-8.

2. Wallensteen M, Dahlquist G, Persson B, Landin-Olsson M, Lernmark Å, Sundkvist G, Thalme B. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia. 1988 Sep 1;31(9):664-9.

3. Mortensen HB, Hougård P, Swift P, Hansen L, Holl RW, Hoey H, Bjoemdalen H, De Beaufort C, Chiarelli F, Danne T, Schoenle EJ. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes care. 2009 Aug 1;32(8):1384-90.

4. Sullivan CA, Cacicedo JM, Rajendran I, Steenkamp DW. Comparison of proinsulin and C-peptide secretion in healthy versus long-standing type 1 diabetes mellitus cohorts: A pilot study. PloS one. 2018 Nov 9;13(11):e0207065.

5. Watkins RA, Evans-Molina C, Terrell JK, Day KH, Guindon L, Restrepo IA, Mimira RG, Blum JS, DiMeglio LA. Proinsulin and heat shock protein 90 as biomarkers of beta-cell stress in the early period after onset of type 1 diabetes. Translational Research. 2016 Feb 1;168:96-106.

6. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R. International consensus on use of continuous glucose monitoring. Diabetes care. 2017 Dec 1;40(12):1631-40.

7. Dhahir FJ, Cook DB, Self CH. Amplified enzyme-linked immunoassay of human proinsulin in serum (detection limit: 0.1 pmol/L). Clinical chemistry. 1992 Feb 1;38(2):227-32.

8. Leighton E, Sainsbury CA, Jones GC. A practical review of C-peptide testing in diabetes. Diabetes therapy. 2017 Jun 1;8(3):475-87.

9. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. www.OpenEpi.com, updated 2013/04/06, accessed 2020/03/31.

10. Derosa G, Salvadeo SA, Mereu R, D'Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, Tinelli C. Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. Diabetes technology & therapeutics. 2009 Mar 1;11(3):159-69.

11. Chiavaroli V, Derraik JG, Jalaludin MY, Albert BB, Ramkumar S, Cutfield WS, Hofman PL, Jefferies CA. Partial remission in type 1 diabetes and associated factors: Analysis based on the insulin dose-adjusted hemoglobin A1c in children and adolescents from a regional diabetes center, Auckland, New Zealand. Pediatric diabetes. 2019 Nov;20(7):892.

12. Cengiz E., Cheng P., Ruedy K.J., Tamborlane WV et al. Clinical outcomes in youth beyond the first year of type 1 diabetes: Results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study. Pediatr Diabetes. 2017 Nov;18(7):566-573.

13. Böber E, Dündar B, Büyükgüzey A. Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab. 2001;14(4):435-41.

14. Meng X, Gong C, Cao B, Peng X, Wu D, Gu Y, Wei L, Liang X, Liu M, Li W, Su C. Glucose fluctuations in association with oxidative stress among children with T1DM: comparison of different phases. The Journal of Clinical Endocrinology & Metabolism. 2015 May 1;100(5):1828-36.

15. Truyen I, De Pauw P, Jørgensen PN, Van Schravendijk C, Ubani O, Decoche K, Vandemeulebroucke E, Weets I, Mao R, Pipeleers DG, Gorus FK. Proinsulin levels and the proinsulin: c-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia. 2005 Nov 1;48(11):2322-9.

16. Schölin A, Nyström L, Arnegård H, Bolinder J, Björk E, Berne C, Karlsson FA, Diabetes Incidence Study Group in Sweden (DISS). Proinsulin/C-peptide ratio, glucagon and remission in new-onset Type 1 diabetes mellitus in young adults. Diabetic medicine. 2011 Feb;28(2):156-61.

17. Sims EK, Bahnson HT, Nyalwidhe J, Haataja L, Davis AK, Speake C, DiMeglio LA, Blum J, Morris MA, Mirmira RG, Nadler J. Proinsulin secretion is a persistent feature of type 1 diabetes. Diabetes care. 2019 Feb 1;42(2):258-64.
18. Steenkamp DW, Cacicedo JM, Sahin-Efe A, Sullivan C, Sternthal E. Preserved proinsulin secretion in long-standing type 1 diabetes. Endocrine Practice. 2017 Nov 16;23(12):1387-93.

19. Leelarathna L, Wilmot EG. Flash forward: a review of flash glucose monitoring. Diabetic Medicine. 2018 Apr;35(4):472-82.

Tables

Table 1. The demographic characteristics and laboratory findings of the diabetic groups

|                          | Honeymoon group (n:21) | Non-honeymoon group (n:31) | P value |
|--------------------------|------------------------|-----------------------------|---------|
| Age (year)               | 9.3(5-13.7)            | 8.9                         | 0.67    |
| Gender (female/male)     | 9/12                   | 16/15                       | 0.259   |
| Diabetes duration (years)| 0.570.5(0.04-1.7)      | 4.31.5(2.2-8.7)             | <0.001  |
| Daily insulin dose (u/kg)| 0.30.11 (0.13-0.5)     | 0.81(0.55-1.25)             | <0.001  |
| HbA1c (%) (mmol/mol)     | 6.4(46)0.6(-17)((5.2(33)-7.6(60)) | 7.2(55)0.6(-17)((6.2(44)-8.3(67)) | <0.001  |
| IDDA1C (%)(mmol/mol)     | 0.7(0.16)((6.8(51)-8.9(74)) | 10.3(89)0.8(-0.15)((8.6(70)-11.9(107)) | <0.001  |
| Estimated HbA1c (%)      | 6.0.8(4.6-8.1)         | 7.6 0.9(6.1-9.7)            | 0.006   |
| CP level (pmol/L)        | 739.8537.8(288-2582)   | 465.6102.6-1854)            | 0.002   |
| PI level (pmol/L)        | 3.9                    | 0.48(0.04-1.3)              | <0.001  |
| PI:C ratio               | 0.55                   | 0.13                        | <0.001  |
|                          | 0.0055                 | 0.0013(0.00016-0.003)       |         |

* IDDA1C: Insulin Dose Adjusted HbA1C, CP: C-peptide, PI: Proinsulin, PI:C: Proinsulin to C-peptide ratio

Table 2. Glycemic parameters of the diabetic groups
### Table 3. Correlations between PI, CP, PI:C ratio and glycemic parameters

| Parameter                                                                 | Honeymoon group (n:21) | Non-honeymoon group (n:31) | P value |
|---------------------------------------------------------------------------|-------------------------|-----------------------------|---------|
| Sensor glucose (mean) (mmol/L) Day-time (06-00)                            | (1.2-10)                | (7.3-12.8)                  | 0.001   |
| Sensor glucose (mean) (mmol/L) Night-time (00-06)                         | (4.2-11)                | (6.2-13.7)                  | 0.002   |
| CV overall (mean) %                                                       | 35 (21-44)              | 40.56 (32-56)               | <0.001  |
| CV day-time (mean) %                                                      | 32.14.7(21-42)          | 40.66(33-54)                | <0.001  |
| CV night-time (mean) %                                                    | 2919-45)                | 38.2                        | <0.001  |
| SD overall (mean) (mmol/L)                                                | (1-3.7)                 | (2.7-5.2)                   | <0.001  |
| SD day-time (mean) (mmol/L)                                               | (1-3.6)                 |                             | <0.001  |
| SD night-time (mean) (mmol/L)                                             | (0.9-4.1)               |                             | <0.001  |
| Overall time-in-range (3.9-10 mmol/L (%))                                  | 76.211.6(46.9-96.2)     | 50.17.4(9-78.8)             | <0.001  |
| Time-in-range (daytime) (%)                                               | 7611.5(48.8-97.4)       | 50.117.4(9.6-79.9)          | <0.001  |
| Time-in-range (night-time) (%)                                            | 75.9.7(38.9-93)         | (6.5-77.7)                  | <0.001  |
| Time in level 1 hypoglycemia(<3.9mmol/L) overall (%) (median)            | 2 (0.2-28.6)            | 5.2 (0.1-19.5)              | 0.056   |
| Time in level 1 hypoglycemia(<3.9mmol/L) day-time (%) (median)           | 4.4 (0.15-18.5)         |                             | 0.039   |
| Time in level 1 hypoglycemia(<3.9mmol/L) night-time (%) (median)         | 1.8 (0-44)              | 4.1 (0-31)                  | 0.185   |
| Time in level 1 hyperglycemia(>10mmol/L) overall (%) (median)            | 19.8(0-50)              | 37.1(4-73)                  | <0.001  |
| Time in level 1 hyperglycemia(>10mmol/L) day-time (%) (median)           | 22.4 (0-49)             | 38.6 (4.2-71.6)             | <0.001  |
| Time in level 1 hyperglycemia(>10mmol/L) night-time (%) (median)         | 13.3 (0-60)             | 36.7 (1.6-77.4)             | 0.001   |

*CV: Coefficient of variation, SD: Standard Deviation*
|                         | Honeymoon | Non-honeymoon | Honeymoon | Non-honeymoon | Honeymoon | Non-honeymoon | Honeymoon | Non-honeymoon | Honeymoon | Non-honeymoon |
|-------------------------|-----------|---------------|-----------|---------------|-----------|---------------|-----------|---------------|-----------|---------------|
| **C-peptide**           |           |               |           |               |           |               |           |               |           |               |
| Time in range Overall   | **r₁:0.65** | **r₂:0.09**   | **r₁:0.56** | **r₂:0.61**   | **r₁:0.27** | **r₂:0.06**   | **r₁:0.47** | **r₂:0.01**   | **r₁:0.62** | **r₂:0.191**   |
| Time in Level 1         | **P₁:0.03** | **P₂:0.7**    | **P₁:0.015** | **P₂:0.009**  | **P₁:0.26** | **P₂:0.98**   | **P₁:0.048** | **P₂:0.95**   | **P₁:0.006** | **P₂:0.462**   |
| Time in Level 1 Hypoglycemia Overall |           |               |           |               |           |               |           |               |           |               |
| Time in Level 1 Hyperglycemia Overall |           |               |           |               |           |               |           |               |           |               |
| Mean HbA1C              |           |               |           |               |           |               |           |               |           |               |
| Mean Sensor Glucose Overall |           |               |           |               |           |               |           |               |           |               |
| Mean SD Overall         |           |               |           |               |           |               |           |               |           |               |
| Mean CV Overall         |           |               |           |               |           |               |           |               |           |               |
| Proinsulin              |           |               |           |               |           |               |           |               |           |               |
| Time in range Overall   | **r₁:0.23** | **r₂:0.94**   | **r₁:0.16** | **r₂:0.07**   | **r₁:0.16** | **r₂:0.24**   | **r₁:0.24** | **r₂:0.16**   | **r₁:0.22** | **r₂:0.02**   |
| Time in Level 1         | **P₁:0.34** | **P₂:0.45**   | **P₁:0.52** | **P₂:0.765**  | **P₁:0.50** | **P₂:0.53**   | **P₁:0.15** | **P₂:0.52**   | **P₁:0.22** | **P₂:0.02**   |
| Time in Level 1 Hypoglycemia Overall |           |               |           |               |           |               |           |               |           |               |
| Time in Level 1 Hyperglycemia Overall |           |               |           |               |           |               |           |               |           |               |
| Mean HbA1C              |           |               |           |               |           |               |           |               |           |               |
| Mean Sensor Glucose Overall |           |               |           |               |           |               |           |               |           |               |
| Mean SD Overall         |           |               |           |               |           |               |           |               |           |               |
| Mean CV Overall         |           |               |           |               |           |               |           |               |           |               |
| Proinsulin to C-peptide ratio |           |               |           |               |           |               |           |               |           |               |
| Time in range Overall   | **r₁:0.06** | **r₂:0.35**   | **r₁:0.01** | **r₂:0.55**   | **r₁:0.15** | **r₂:0.28**   | **r₁:0.09** | **r₂:0.37**   | **r₁:0.18** | **r₂:0.02**   |
| Time in Level 1         | **P₁:0.78** | **P₂:0.62**   | **P₁:0.11** | **P₂:0.02**   | **P₁:0.54** | **P₂:0.27**   | **P₁:0.95** | **P₂:0.13**   | **P₁:0.79** | **P₂:0.48**   |
| Mean HbA1C              |           |               |           |               |           |               |           |               |           |               |
| Mean Sensor Glucose Overall |           |               |           |               |           |               |           |               |           |               |
| Mean SD Overall         |           |               |           |               |           |               |           |               |           |               |
| Mean CV Overall         |           |               |           |               |           |               |           |               |           |               |

*CV: Coefficient of variation, SD: Standard Deviation, P1:C: Proinsulin to C-peptide ratio*